Peripheral administration of brain-derived neurotrophic factor to Rett syndrome animal model: A possible approach for the treatment of Rett syndrome

Medical Science Monitor

Volumn 18, Issue 8, 2012, Pages

  Tsai, Shih Jen ^a,b  

^a TAIPEI VETERANS GENERAL HOSPITAL   (Taiwan)

^b NATIONAL YANG MING UNIVERSITY   (Taiwan)

Author keywords

Blood brain barrier; Brain derived neurotrophic factor; Peripheral administration; Rett syndrome; Treatment

Indexed keywords

BRAIN DERIVED NEUROTROPHIC FACTOR RECEPTOR; MANNITOL;

ANIMAL MODEL; ARTICLE; BLOOD BRAIN BARRIER; DRUG EFFECT; MOUSE; NONHUMAN; RETT SYNDROME;

EID: 84866064039     PISSN: 12341010     EISSN: 16433750     Source Type: Journal    
DOI: 10.12659/MSM.883251     Document Type: Article

References (33)

1. Segawa M, Nomura Y: Rett syndrome. Curr Opin Neurol, 2005; 18: 97-104
2. Gadalla KK, Bailey ME, Cobb SR: MeCP2 and Rett syndrome: reversibility and potential avenues for therapy. Biochem J, 2011; 439: 1-14
3. Percy AK: Rett syndrome: exploring the autism link. Arch Neurol, 2011; 68: 985-89
4. Amir RE, Van den Veyver IB, Wan M et al: Rett syndrome is caused by mutations in X-linked MECP2, encoding methyl-CpG-binding protein 2. Nat Genet, 1999; 23: 185-88
5. Segawa M: Pathophysiology of Rett syndrome from the standpoint of clinical characteristics. Brain Dev, 2001; 23(Suppl.1): S94-98
6. Panayotis N, Ghata A, Villard L, Roux JC: Biogenic amines and their metabolites are differentially affected in the Mecp2-deficient mouse brain. BMC Neurosci, 2011; 12: 47
7. Nomura Y, Segawa M: Natural history of Rett syndrome. J Child Neurol, 2005; 20: 764-68
8. Johnston MV, Blue ME, Naidu S: Rett syndrome and neuronal development. J Child Neurol, 2005; 20: 759-63
9. Maisonpierre PC, Belluscio L, Friedman B et al: NT-3, BDNF, and NGF in the developing rat nervous system: parallel as well as reciprocal patterns of expression. Neuron, 1990; 5: 501-9
10. Tuszynski MH, Gage FH: Neurotrophic factors and diseases of the nervous system. Ann Neurol, 1994; 35: S9-S12
11. Karege F, Schwald M, Cisse M: Postnatal developmental profile of brainderived neurotrophic factor in rat brain and platelets. Neurosci Lett, 2002; 328: 261-64
12. Pezet S, Malcangio M: Brain-derived neurotrophic factor as a drug target for CNS disorders. Expert Opin Ther Targets, 2004; 8: 391-99
13. Encinas M, Iglesias M, Llecha N, Comella JX: Extracellular-regulated kinases and phosphatidylinositol 3-kinase are involved in brain-derived neurotrophic factor-mediated survival and neuritogenesis of the neuroblastoma cell line SH-SY5Y. J Neurochem, 1999; 73: 1409-21
14. Chang Q, Khare G, Dani V et al: The disease progression of mecp2 mutant mice is affected by the level of BDNF expression. Neuron, 2006; 49: 341-48
15. Kline DD, Ogier M, Kunze DL, Katz DM: Exogenous brain-derived neurotrophic factor rescues synaptic dysfunction in Mecp2-null mice. J Neurosci, 2010; 30: 5303-10
16. Larimore JL, Chapleau CA, Kudo S et al: Bdnf overexpression in hippocampal neurons prevents dendritic atrophy caused by Rett-associated MECP2 mutations. Neurobiol Dis, 2009; 34: 199-211
17. Zeev BB, Bebbington A, Ho G et al: The common BDNF polymorphism may be a modifier of disease severity in Rett syndrome. Neurology, 2009; 72: 1242-47
18. Tsai SJ: Lithium and antidepressants: Potential agents for the treatment of Rett syndrome. Med Hypotheses, 2006; 67: 626-29
19. Ben-Zeev B, Aharoni R, Nissenkorn A, Arnon R: Glatiramer acetate (GA, Copolymer-1) an hypothetical treatment option for Rett syndrome. Med Hypotheses, 2011: 76: 190-93
20. Roux JC, Dura E, Moncla A et al: Treatment with desipramine improves breathing and survival in a mouse model for Rett syndrome. Eur J Neurosci, 2007; 25: 1915-22
21. Zanella S, Mebarek S, Lajard AM et al: Oral treatment with desipramine improves breathing and life span in Rett syndrome mouse model. Respir Physiol Neurobiol, 2008; 160: 116-21
22. Pan CH, Tsai SJ: Early intervention with psychostimulants or antidepressants to increase methyl-CpG-binding protein 2 (MeCP2) expressions: a potential therapy for Rett syndrome. Med Sci Monit, 2012; 18(1): HY1-3
23. Pan W, Banks WA, Fasold MB et al: Transport of brain-derived neurotrophic factor across the blood-brain barrier. Neuropharmacology, 1998; 37: 1553-61
24. Zhang Y, Pardridge WM: Blood-brain barrier targeting of BDNF improves motor function in rats with middle cerebral artery occlusion. Brain Res, 2006; 1111: 227-29
25. Poduslo JF, Curran GL: Permeability at the blood-brain and blood-nerve barriers of the neurotrophic factors: NGF, CNTF, NT-3, BDNF. Brain Res Mol Brain Res, 1996; 36: 280-86
26. Schmidt HD, Duman RS: Peripheral BDNF produces antidepressant-like effects in cellular and behavioral models. Neuropsychopharmacology, 2010; 35: 2378-91
27. Alcalá-Barraza SR, Lee MS, Hanson LR et al: Intranasal delivery of neurotrophic factors BDNF, CNTF, EPO, and NT-4 to the CNS. J Drug Target, 2010; 18: 179-90
28. Binder DK, Croll SD, Gall CM, Scharfman HE: BDNF and epilepsy: too much of a good thing? Trends Neurosci, 2001; 24: 47-53
29. Tsai SJ: Is mania caused by overactivity of central brain-derived neurotrophic factor? Med Hypotheses, 2004; 62: 19-22
30. Govindarajan A, Rao BS, Nair D et al: Transgenic brain-derived neurotrophic factor expression causes both anxiogenic and antidepressant effects. Proc Natl Acad Sci USA, 2006; 103: 13208-13
31. Pearse RN, Swendeman SL, Li Y et al: A neurotrophin axis in myeloma: TrkB and BDNF promote tumor-cell survival. Blood, 2005; 105: 4429-36
32. Yasuhara T, Hara K, Maki M et al: Mannitol facilitates neurotrophic factor upregulation and behavioral recovery in neonatal hypoxic-ischemic rats with human umbilical cord blood grafts. J Cell Mol Med, 2010; 14: 914-21
33. Better OS, Rubinstein I, Winaver JM, Knochel JP: Mannitol therapy revisited (1940-1997). Kidney Int, 1997; 52: 886-94